Once-weekly subcutaneous administration of the novel recombinant, humanized, IgG4 bispecific antibody emicizumab prevents or reduces bleeds in patients with haemophilia A and factor VIII inhibitors in the phase III HAVEN 1* trial, offering a potential new standard of care for this severe bleeding disorder.
Rosuvastatin led to improved coagulation profile, in particular lower levels of factor VIII procoagulant activity (VIII:C), among patients who had venous thrombosis (VT) previously, suggesting that statins could reduce the risk of recurrent VT, according to a study presented at the ISTH 2017 Congress in Berlin, Germany.
Gene-transfer therapy using adeno-associated virus in patients with severe haemophilia A resulted in sustained levels of coagulation factor VIII (FVIII) expression within 1 year of observation, reducing spontaneous bleeds and FVIII infusions in most patients, interim results of a phase 1/2 dose-escalation study have shown.
Idarucizumab, a dabigatran-reversing humanized monoclonal antibody fragment, rapidly, completely, and durably reversed the anticoagulant effect of dabigatran in elderly patients with life-threatening bleeding or undergoing invasive medical interventions, according to a full cohort analysis of the RE-VERSE AD* study presented at the ISTH 2017 Congress in Berlin, Germany.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Patients with psoriatic arthritis (PsA) often suffer from liver abnormalities, which are associated with higher body mass index (BMI), daily consumption of alcohol, more severe disease, and some therapies, according to a recent study.
Pembrolizumab in combination with chemotherapy significantly improves progression-free survival (PFS) vs chemotherapy alone in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC), results of the KEYNOTE-355 study have shown.